Related Experiment Video
Updated: Jun 12, 2025
12:57
Investigating the Spreading and Toxicity of Prion-like Proteins Using the Metazoan Model Organism C. elegans
Published on: January 8, 2015
15.8K
The prion principle and Alzheimer's disease
Lary C Walker1,2, Mathias Jucker3,4
1Department of Neurology, Emory University, Atlanta, GA, USA.
Science (New York, N.Y.)
|September 19, 2024
Abstract:
Similarities to molecular mechanisms underlying prion diseases may help to refine Alzheimer's disease therapies.
Insights
Molecular similarities between prion diseases and Alzheimer's disease could lead to improved therapeutic strategies for Alzheimer's. Understanding these shared mechanisms is key to developing new treatments.
Area of Science:
- Neurodegenerative diseases
- Molecular biology
- Prion science
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder.
- Prion diseases are a group of fatal neurodegenerative conditions caused by misfolded proteins.
- Shared molecular pathways are increasingly recognized between AD and prion diseases.
Purpose of the Study:
- To explore the molecular similarities between Alzheimer's disease and prion diseases.
- To identify potential therapeutic targets for Alzheimer's disease based on prion disease mechanisms.
Main Methods:
- Comparative analysis of protein misfolding pathways.
- Review of existing literature on molecular mechanisms in both disease types.
Main Results:
- Evidence suggests commonalities in protein aggregation and propagation.
- Specific molecular players may be shared across both neurodegenerative conditions.
Conclusions:
- The molecular underpinnings of prion diseases offer valuable insights for Alzheimer's disease therapy development.
- Targeting shared mechanisms could refine existing and novel Alzheimer's treatment strategies.
Related Concept Videos
03:03Amyloid Fibrils
9.3K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.3K
01:26Alzheimer's Disease: Overview
451
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
451
01:22Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
01:15Parkinson's Disease: Overview
495
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
495